Page 181 - CW E-Magazine (18-6-2024)

P. 181

Special Report

Manufacturing & supply lines: Small-molecule APIs
MANUFACTURER & EXPORTER

mall-molecule drugs still dominate ment over 2022 levels, which represented PATRICIA VAN ARNUM A GMP, ISO ( 9001:2015, 14001:2015 and 45001:2018), FSSAI, HALAL & KOSHER CERTIFIED COMPANY
new drug approvals, as measured a recent low in small-molecule drug ap- Editorial Director AVAILABLE IN GRADE : IP/BP/USP/EP/FCC
Sby the number of new molecular provals. The decrease in small molecules’ Drug, Chemical & Associated
entities approved by the FDA’s Center share of new drug approvals in 2022 was • ALUMINIUM SULPHATE Cas.7784-31-8 • MAGNESIUM SULPHATE 7H2O Cas.10034-99-8 • SODIUM PHOSPHATE DIBASIC
for Drug Evaluation and Research, but are largely due to the overall decline in new Technologies Association,Inc. (DCAT) • AMMONIUM MOLYBDATE Cas.12054-85-2 • MAGNESIUM SULPHATE DRIED CAS.7487-88-9 HEPTAHYDRATE CAS.7782-85-6
• SODIUM PHOSPHATE DIBASIC DIHYDRATE
• AMMONIUM PHOSPHATE Cas.7783-28-0
• MAGNESIUM SULPHATE ANHYDROUS CAS.
they translating into market success? drug approvals in 2022 and a correspond-  Astellas’ Veozah (fezolinetant) for re- • BISMUTH SUBCARBONATE Cas.5892-10-4 7487-88-9 CAS.10028-24-7
DCAT Value Chain Insights takes a look ing decline in small-molecule drug ap- ducing moderate-to-severe vasomotor • BISMUTH SUBNITRATE CAS.1304-85-4 • MAGNESIUM OXIDE CAS 1309-48-4 • SODIUM PHOSPHATE DIBASIC
on the market for drugs with small-mole- provals and a rise in new biologic drug symptoms due to menopause; • BENZOIC ACID CAS.65-85-0 • POTASSIUM BI CARBONATE CAS.298-14-6 MONOHYDRATE CAS.118830-14-1
cule active pharmaceutical ingredients approvals. In 2022, FDA’s CDER ap-  AstraZeneca’s Truqap (capivasertib) • BORAX SODIUM BORATE CAS.1330-43-4 • POTASSIUM BI SULPHATE CAS.7646-93-7 • SODIUM PHOSPHATE TRIBASIC
and related supply-demand fundamen- proved 22 new small-molecule drugs and for treating advanced HR-positive • BORIC ACID CAS.10043-35-3 • POTASSIUM CARBONATE CAS.584-08-7 DODECAHYDRATE CAS.10101-89-0
tals. 15 new biologics. The 17 new biologics breast cancer; • CALAMINE CAS 8011-96-9 • POTASSIUM CHLORIDE CAS.7440-09-7 • SODIUM PHOSPHATE TRIBASIC ANHYDROUS
CAS.7601-54-9
• POTASSIUM NITRATE CAS.7757-79-1
• CALCIUM CARBONATE CAS.471-34-1
approvals in 2023 surpassed 2022 levels  Bausch and Lomb’s Miebo (perﬂ uoro- • CALCIUM CHLORIDE DIHYDRATE CAS. • POTASSIUM IODIDE CAS.7681-11-0 • SODIUM NITRITE CAS.7632-00-0
Overall new drug approvals in 2023 and matched a recent high in 2018, when hexyloctane ophthalmic solution) for 10035-04-8 • POTASSIUM PHOSPHATE MONOHYDRATE • SODIUM SULPHATE CAS 7757-82-6
Last year (2023) saw an uptick in new 17 new biologics were also approved by treating dry-eye disease; • CALCIUM SULPHATE CAS.7778-18-9 CAS.7778-77-0 • SODIUM SULPHITE CAS.7757-83-7
drug approvals compared to 2022, which FDA’s CDER. The 17 new biologic drug  Biogen’s Qalsody (tofersen) for treating • CALCIUM PHOSPHATE DI BASIC DIHYDRATE • POTASSIUM PHOSPHATE DIBASIC CAS. • STANNOUS CHLORIDE CAS 10025-69-1
was a recent dip in new drug approvals. approvals in 2023 far exceeded approvals amyotrophic lateral sclerosis (ALS, CAS 7789-77-7 7758-11-4 • SALICYLIC ACID CAS.69-72-7
The US Food and Drug Administration’s of new therapeutic biologics by FDA’s i.e., Lou Gehrig’s disease); • CALCIUM PHOSPHATE DI BASIC ANHYDROUS • POTASSIUM SODIUM TARTRATE CAS 6381-59-5 • SODIUM SELENITE PENTAHYDRATE
• POTASSIUM SULPHATE CAS.7778-80-5
CAS.7757-93-9
CAS.26970-82-1
Center for Drug Evaluation and Research CDER of 14 in 2021, 13 in 2020, and 10  GlaxoSmithKline’s Jesduvroq (da- • CALCIUM PHOSPHATE TRIBASIC CAS 7758-87-4 • POTASSIUM BROMIDE CAS.7758-02-03 • UREA CAS.57-13-6
(CDER) approved 55 new molecular enti- in 2019. produstat) for treating anaemia due to • CUPRIC SULPHATE PENTAHYDRATE CAS • SODIUM BI CARBONATE CAS .144-55-8 • ZINC CARBONATE CAS.3486-35-9
ties (NMEs) and new therapeutic biologics chronic kidney disease; 7758-99-8 • SODIUM FLUORIDE CAS .7681-49-4 • ZINC OXIDE CAS 1314-13-2
in 2023, a 49% increase in the number of Small-molecules and ﬁ rst-in-class drugs  Novartis’ Fabhalta (iptacopan) for • CUPRIC SULPHATE ANHYDROUS CAS.7758-98-7 • SODIUM MONOFLUORO PHOSPHATE CAS. • ZINC SULPHATE HEPTAHYDRATE CAS.
new drug approvals compared to 2022, Aside from just the overall number treating paroxysmal nocturnal haemo- • COPPER CARBONATE CAS.12069-69-1 10163-15-2 7646-20-0
when 37 new drugs were approved. The of new drug approvals, product innova- globinuria, a rare blood disorder; • CUPRIC CHLORIDE CAS.10125-13-0 • SODIUM NITRATE CAS 7631-99-4 • ZINC SULPHATE MONOHYDRATE CAS.
7446-19-7
• FERROUS SULPHATE DRIED CAS.13463-43-9
• SODIUM PHOSPHATE MONOBASIC DIHYDRATE
55 new drugs approved in 2023 by FDA’s tion can also be evaluated by the num-  Novo Nordisk’s Rivﬂ oza (nedosiran) • FERROUS SULPHATE HEPTAHYDRATE CAS. CAS.13472-35-0 • ZINC CHLORIDE CAS. 7646-85-7
CDER was in line with recent years. In ber of new drug approvals classiﬁ ed as for treating primary hyperoxaluria, a 7782-63-0 • MAGNESIUM PHOSPHATE DI BASIC CAS • MAGNESIUM PHOSPHATE TRIBASIC CAS.
2021, 50 NMEs and new therapeutic bio- “ﬁ rst-in-class,” which FDA’s CDER rare condition characteriwed by recur- • MANGANESE SULPHATE MONOHYDRATE CAS. 7782-75-4 • SODIUM PHOSPHATE MONOBASIC 7757-87-1
logics were approved by FDA’s CDER characterizes as drugs with a different rent kidney and bladder stones; and 10034-96-5 ANHYDROUS CAS.7558-80-7
and 53 in 2020. The 55 new drugs ap- mechanism of action than existing drugs.  Pﬁ zer’s Paxlovid (nirmatrelvir tablets; • MANGANESE CHLORIDE CAS. 13446-34-9 • SODIUM PHOSPHATE DIBASIC ANHYDROUS
proved in 2023 represented the second In 2023, FDA’s CDER approved 20 new ritonavir tablets, co-packaged) for • MAGNESIUM CARBONATE Cas.546-93-0 CAS.7558-80-7
highest level of approvals in the past drugs that it characterized as ﬁ rst-in- treating COVID-19. • MAGNESIUM CHLORIDE HEXAHYDRATE • SODIUM PHOSPHATE DIBASIC
Cas.7791-18-6
DODECAHYDRATE CAS.10039-32-4
decade, except for 2018 when 59 new class, which represented approximately
drugs were approved. 36% of new drug approvals. Of these Although small-molecule drugs were SPECIAL PRODUCTS WE MAKE IN OUR FACTORY
20 ﬁ rst-in-class new drug approvals, 17 well represented with 85% of the ﬁ rst-in-
Small-molecule new drug approvals were small molecules, representing 85% class new drug approvals in 2023, more POTASSIUM DICHROMATE LR BORIC ACID POWDER AR
In 2023, FDA’s CDER approved 38 of ﬁ rst-in-class new drug approvals in than half of these drugs were for niche POTASSIUM CHROMATE LR POTASSIUM PHOSPHATE LR /AR
small-molecule products, representing 69% 2023 by FDA’s CDER. Of these 17 ﬁ rst- indications. Of the 17 small-molecule STARCH (POTATO SOLUBLE) LR SODIUM NITRATE LR /AR
of new drug approvals (see Figure 1). in-class, small-molecule new drug ﬁ rst-in-class drug approvals in 2023, COPPER SULPHATE ANHYDROUS LR SODIUM CARBONATE ANHYDROUS (GRANULAR)
The percentage of small-molecule ap- approvals in 2023, eight were from large nine, or 53%, were for treating orphan/ FOR CATALOGUE COMPANIES IN LR GRADE
provals in 2023 was in line with recent to mid-sized bio/pharma companies. rare diseases, deﬁ ned as a disease affect-
year, except in 2022, which represented a These eight drugs were: ing 200,000 individuals or less in the US. BISMUTH NITRATE / SUBNITRATE / OXIDE / OXYCHLORIDE / SULPHATE / CARBONATE
recent low. In 2022, 59% of the new drug IODIDE OF AMMONIUM / CADMIUM / LEAD / BARIUM/STRONTIUM
approvals by FDA’s CDER were small NICKEL / SULPHATE / CHLORIDE / CARBONATE / NITRATE / AMMONIUM SULPHATE
molecules or 22 of the 37 new drug ap- 69% 59% 72% 75% 79% STRONTIUM / BROMIDE / CARBONATE / CHLORIDE / NITRATE / SULPHATE
provals. Between 2018 and 2021, small QUALIKEMS LIFESCIENCES PVT. LTD.
molecules averaged 74% of new drug
approvals. In 2021, small molecules re- 2023: 55 new 2022: 37 new drugs 2021: 50 new drugs 2020: 53 new 2019: 48 new drugs H.O & WORKS: Plot No.68-69, G.I.D.C Industrial Estate, Nandesari,
presented 72% of new drug approvals, 75% drugs approved; 38 approved; 22 small approved; 36 small drugs approved; 40 approved; 38 small Vadodara - 391340 (GUJARAT).
molecules
molecules
small molecules
molecules
small molecules
in 2020, and 79% in 2019.
Fig. 1: Percentage of new drug approvals by the US FDA’s CDER that were small molecules Telefax : + 91-265-2841531,32,34,35 • Mobile: +91-92275 36999
Small molecule approvals are NMEs approved via a New Drug Application (NDA) by the CDER; NDA Email: salesindia@qualikems.com & Info@qualikems.com
The 69% of new drug approvals being approvals include drugs and diagnostic agents.
small molecules in 2023 was an improve- Source: CDER Web : www.qualikems.com
KNS ADI
180 Chemical Weekly June 18, 2024 Chemical Weekly June 18, 2024 181
Contents Index to Advertisers Index to Products Advertised

176 177 178 179 180 181 182 183 184 185 186